A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
The purpose of the study is to compare the effects, good and bad, of the study drug (TH-302) in combination with doxorubicin with doxorubicin alone on you and your soft tissue sarcoma.
Locally advanced unresectable or metastatic soft tissue sarcoma
Age 15 or over diagnosed with locally advanced unresectable or metastatic soft tissue sarcoma with no prior systemic treatment. Blood work, imaging, and heart scans will be performed to determine eligibility upon consent.
15 - 120
Healthy Volunteers Needed
Duration of Participation
Treatment will last for approximately 5 months. Follow up will last for up to 36 months post first dose of study treatment.